{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-033437","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2024-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.422655+00:00","generated_at":"2026-05-31T15:16:35.079926+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Nasdaq grants Avalo Therapeutics 180-day extension to regain equity compliance","bullets":["Reported stockholders' equity of negative $112.5M as of March 31, 2024, falling short of Nasdaq's $2.5M minimum.","Received Nasdaq Staff deficiency notice on May 20, 2024 for non-compliance with Listing Rule 5550(b)(1).","On July 29, 2024, Nasdaq granted a 180-day extension to November 18, 2024 to regain compliance.","Company submitted a compliance plan; no assurance it will regain compliance by the deadline."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-033437","json":"https://secwatch.observer/filing/0001628280-24-033437.json","markdown":"https://secwatch.observer/filing/0001628280-24-033437.md","text":"https://secwatch.observer/filing/0001628280-24-033437.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828024033437/0001628280-24-033437-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828024033437/avtx-20240729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:16:35.079926+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}